Radioactive 'Tumor Seeker' drug enters first human trials for tough cancers
NCT ID NCT05283330
Summary
This is a first-in-human study testing a new experimental drug called 212Pb-DOTAM-GRPR1 in adults with advanced cancers that have returned or spread. The main goal is to find a safe and tolerable dose. Researchers will also check if the drug, which delivers radiation directly to tumors, shows early signs of helping to control cancer growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Advanced Molecular Imaging and Therapy
RECRUITINGGlen Burnie, Maryland, 21061, United States
Contact Phone: •••-•••-••••
Contact
-
Northwestern University Robert H Lurie Medical Research
RECRUITINGChicago, Illinois, 60611, United States
Contact Email: •••••@•••••
Contact
-
UK Markey Cancer Center
RECRUITINGLexington, Kentucky, 40536, United States
Contact Phone: •••-•••-••••
Contact
-
XCancer Omaha / Urology Cancer Center
RECRUITINGOmaha, Nebraska, 68130, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.